Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep;59(9):5475-82.
doi: 10.1128/AAC.00507-15. Epub 2015 Jun 29.

Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda

Affiliations

Prevalence of Plasmodium falciparum resistance markers to sulfadoxine-pyrimethamine among pregnant women receiving intermittent preventive treatment for malaria in Uganda

Anthony K Mbonye et al. Antimicrob Agents Chemother. 2015 Sep.

Abstract

The aim of this study was to assess the prevalence of mutations in Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes among pregnant women using sulfadoxine-pyrimethamine (SP) as an intermittent preventive treatment (IPTp). A molecular epidemiological study of P. falciparum parasite resistance markers to SP was conducted from August 2010 to February 2012 in Mukono district in central Uganda. DNA was extracted from 413 P. falciparum-positive samples. Real-time PCR, followed by melting curve analysis, was used to characterize point mutations in the Pfdhfr and Pfdhps genes that are associated with SP resistance. The prevalence of the single-nucleotide mutations in Pfdhfr at codons 51I, 59R, and 108N and in Pfdhps at codons 437G and 540E was high (>98%), reaching 100% fixation after one dose of SP, while the prevalence of 581G was 3.3% at baseline, reaching 12.5% after one dose of SP. At baseline, the prevalence of Pfdhfr and Pfdhps quintuple mutations was 89%, whereas the sextuple mutations (including 581G) were not prevalent (3.9%), reaching 16.7% after one dose of SP. However, the numbers of infections at follow-up visits were small, and hence there was insufficient statistical power to test whether there was a true rise in the prevalence of this allele. The overall high frequency of Pfdhfr and Pfdhps quintuple mutations throughout pregnancy excluded further analyses of possible associations between certain haplotypes and the risk of lower birth weight and anemia. However, women infected with P. falciparum had 1.3-g/dl-lower hemoglobin levels (P = 0.001) and delivered babies with a 400-g-lower birth weight (P = 0.001) compared to nonparasitemic women. Despite this, 44 women who were P. falciparum positive at baseline became negative after one or two doses of SP (i.e., 50.5%), implying that SP-IPTp still has some efficacy. P. falciparum resistance markers to SP are high in this population, whereas P. falciparum infection was associated with poor birth outcomes.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Recruitment of patients.

References

    1. Brabin BJ. 1983. An analysis of malaria in pregnancy in Africa. Bull World Health Organ 61:1005–1016. - PMC - PubMed
    1. McGregor IA, Wilson ME, Bilewicz WZ. 1983. Malaria infection of the placenta in The Gambia, West Africa, its incidence and relationship to birth weight and placenta weight. Trans R Soc Trop Med Hyg 93:529–534. - PubMed
    1. Uganda Ministry of Health. 2010. Uganda clinical guidelines. Uganda Ministry of Health, Kampala, Uganda.
    1. WHO/MPAC. 2013. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of March 2013 meeting. Malar J 12:213. doi:10.1186/1475-2875-12-213. - DOI - PMC - PubMed
    1. Kayentao K, Garner P, van Eijk AM, Naidoo I, Roper C, Mulokozi A, MacArthur JR, Luntamo M, Ashorn P, Doumbo OK, ter Kuile FO. 2013. Intermittent preventive therapy for malaria during pregnancy using 2 vs. 3 or more doses of sulphadoxine-pyrimethamine and risk of low birth weight in Africa. JAMA 309:594–604. doi:10.1001/jama.2012.216231. - DOI - PMC - PubMed

Publication types